Literature DB >> 19822407

Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study.

Silvana Galderisi1, Michael Davidson, René S Kahn, Armida Mucci, Han Boter, Mihai D Gheorghe, Janusz K Rybakowski, Jan Libiger, Sonia Dollfus, Juan J López-Ibor, Joseph Peuskens, Luchezar G Hranov, Wolfgang W Fleischhacker.   

Abstract

BACKGROUND: Profile and correlates of cognitive deficits in first episode (FE) schizophrenia patients are still debated. The present study is aimed to clarify in a large sample of FE patients the extent of impairment in key cognitive domains and its relationships with demographic and clinical variables.
METHOD: The European First Episode Schizophrenia Trial collected demographic, clinical and neurocognitive baseline data in 498 FE patients with minimal or no prior exposure to antipsychotics. Two-hundred-twenty healthy subjects (HS) were also evaluated. Neurocognitive assessment included the Rey Auditory Verbal Learning Test; Trail Making A and B, Purdue Pegboard and Digit-Symbol Coding.
RESULTS: Patients performed worse than HS on all tests (effect sizes from -0.88 to -1.73). Correlations with psychopathological dimensions were weak and involved reality distortion and disorganization. The duration of untreated psychosis (DUP) was not associated with cognitive impairment. Subjects living alone had a better neurocognitive performance, while the occupation status did not reveal any association with cognition.
CONCLUSIONS: A moderate/severe impairment of processing speed, motor dexterity, verbal memory and cognitive flexibility was found in the largest sample of FE patients analyzed so far. The impairment was largely independent from psychopathology and not associated with DUP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19822407     DOI: 10.1016/j.schres.2009.09.022

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  27 in total

1.  [Early dementia as primary syndrome of schizophrenia].

Authors:  F U Lang; R Klug; M Kunath; C Palm; I Uttner; M Jäger
Journal:  Nervenarzt       Date:  2013-05       Impact factor: 1.214

2.  Variation in the nicotinic acetylcholine receptor gene cluster CHRNA5-CHRNA3-CHRNB4 and its interaction with recent tobacco use influence cognitive flexibility.

Authors:  Huiping Zhang; Henry R Kranzler; James Poling; Joel Gelernter
Journal:  Neuropsychopharmacology       Date:  2010-07-14       Impact factor: 7.853

Review 3.  Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment.

Authors:  Trevor Archer; Richard M Kostrzewa; Tomas Palomo; Richard J Beninger
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

4.  Homocysteine and cognition in first-episode psychosis patients.

Authors:  Rosa Ayesa-Arriola; Rocío Pérez-Iglesias; José Manuel Rodríguez-Sánchez; Ignacio Mata; Elsa Gómez-Ruiz; Maite García-Unzueta; Obdulia Martínez-García; Rafael Tabares-Seisdedos; Jose L Vázquez-Barquero; Benedicto Crespo-Facorro
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-02       Impact factor: 5.270

5.  The relationship of neurocognition and negative symptoms to social and role functioning over time in individuals at clinical high risk in the first phase of the North American Prodrome Longitudinal Study.

Authors:  Eric C Meyer; Ricardo E Carrión; Barbara A Cornblatt; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Elaine F Walker; Scott W Woods; Robert Heinssen; Larry J Seidman
Journal:  Schizophr Bull       Date:  2014-02-18       Impact factor: 9.306

Review 6.  Is there evidence for late cognitive decline in chronic schizophrenia?

Authors:  Jharna N Shah; Salah U Qureshi; Ali Jawaid; Paul E Schulz
Journal:  Psychiatr Q       Date:  2012-06

7.  Early markers of cognitive enhancement: developing an implicit measure of cognitive performance.

Authors:  Abbie Pringle; Michael Browning; Elizabeth Parsons; Phil J Cowen; Catherine J Harmer
Journal:  Psychopharmacology (Berl)       Date:  2013-07-03       Impact factor: 4.530

8.  Individual trajectories of cognitive performance in first episode psychosis: a 2-year follow-up study.

Authors:  A M Sánchez-Torres; L Moreno-Izco; R Lorente-Omeñaca; B Cabrera; A Lobo; A M González-Pinto; J Merchán-Naranjo; I Corripio; E Vieta; E de la Serna; A Butjosa; F Contreras; S Sarró; G Mezquida; M Ribeiro; M Bernardo; M J Cuesta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-11-21       Impact factor: 5.270

Review 9.  Amisulpride versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Heike Hunger; Franziska Schmid; Sandra Schwarz; Joaquim I Silveira da Mota Neto; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 10.  Ziprasidone versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Heike Hunger; Sandra Schwarz; Paranthaman Seth S Bhoopathi; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.